Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 132D is a cell-surface adhesion molecule that is highly expressed in the brain and mature oligodendrocytes[1][3]. It features five conserved extracellular domains, including three tandem immunoglobulin domains and a cohesin domain homologue, marking it as part of an ancient and structurally unique cell adhesion protein family[1]. Its intracellular domain contains docking sites for protein phosphatase 1 (PP1) and a WAVE regulatory complex interacting motif, linking extracellular neuronal interactions to actin cytoskeleton dynamics[1]. TMEM132D is implicated in the regulation of neuronal morphology, motility, and migration, and has been associated with several diseases, including panic disorder, non-syndromic hearing loss, and cancer[1]. Its domain architecture and evolutionary conservation suggest physiologically significant roles in CNS cell connectivity and response to genetic variants, warranting deeper investigation as a disease-related target[1][3].
Not established; since no approved drugs target TMEM132D directly, no mechanisms have been characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 132D (TMEM132D).